|Bid||0.2887 x 1200|
|Ask||0.2899 x 3200|
|Day's Range||0.2750 - 0.2888|
|52 Week Range||0.2750 - 2.1200|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced an exclusive option agreement and research collaboration with Kansas State University (K-State) to develop zinc nanoparticle (ZNP) mRNA vaccines. The ZNP technology replaces the lipid-nanoparticle (LNP) technology in current COVID-19 vaccines. Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) COVID-19 shots are based on the LNP platform. The new ZNP technology can confer increased stability to mRNA v
Moody's Vice President and Senior Credit Officer Charlie O'Shea joins Yahoo Finance Live to discuss supply chain disruptions and the effects Omicron is having on the global scale for the consumer industry in 2022.
Marketgauge.com Partner and Director of Trading Research & Education Michele Schneider joins Yahoo Finance Live to discuss the implications of the latest economic data.